Gain Therapeutics (GANX) to Release Quarterly Earnings on Thursday

Gain Therapeutics (NASDAQ:GANX) is expected to be posting its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Gain Therapeutics to post earnings of ($0.14) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Gain Therapeutics Trading Down 25.6%

Shares of NASDAQ GANX opened at $1.95 on Thursday. The company has a quick ratio of 2.52, a current ratio of 2.52 and a debt-to-equity ratio of 0.05. Gain Therapeutics has a 12 month low of $1.41 and a 12 month high of $4.34. The company has a market cap of $75.00 million, a price-to-earnings ratio of -3.20 and a beta of -0.03. The business has a fifty day simple moving average of $2.16 and a 200-day simple moving average of $2.36.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Sprott Inc. acquired a new stake in Gain Therapeutics during the 4th quarter worth about $39,000. Commonwealth Equity Services LLC acquired a new position in shares of Gain Therapeutics in the 4th quarter valued at about $41,000. Millennium Management LLC purchased a new stake in shares of Gain Therapeutics in the fourth quarter worth approximately $45,000. JPMorgan Chase & Co. purchased a new stake in shares of Gain Therapeutics in the third quarter worth approximately $47,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth approximately $47,000. 11.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GANX. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Friday, December 19th. Roth Mkm reiterated a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.00.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.